Hikal Ltd
Pharmaceuticals & Biotechnology | Small Cap
Hikal Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency, growth, and profitability, indicating a solid foundation and effective management in these areas. However, liquidity and efficiency are areas of concern, suggesting potential challenges in meeting short-term obligations and optimizing asset utilization. The company's coverage ratios are reasonably good, reflecting its ability to meet its interest and dividend commitments. While the financial ratios are weak, the other strong areas provide a somewhat balanced view. Overall, Hikal Ltd appears to be a company with considerable strengths in long-term sustainability and earnings potential, but it needs to address its short-term financial management to ensure continued success.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio5.20
- Profitability Ratio10.00
- Efficiency Ratio4.67
- Coverage Ratio8.80
- Solvency Ratio10.00
- Liquidity Ratio2.80
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Hikal Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency, growth, and profitability, indicating a solid foundation and effective management in these areas. However, liquidity and efficiency are areas of concern, suggesting potential challenges in meeting short-term obligations and optimizing asset utilization. The company's coverage ratios are reasonably good, reflecting its ability to meet its interest and dividend commitments. While the financial ratios are weak, the other strong areas provide a somewhat balanced view. Overall, Hikal Ltd appears to be a company with considerable strengths in long-term sustainability and earnings potential, but it needs to address its short-term financial management to ensure continued success.
Overall Valuation Score
P/E RATIO (TTM)
-50.28
Industry Median
28.93
Small Cap Median
26.92
P/E RATIO
-50.15
P/B RATIO
2.04
Industry Median
3.18
Small Cap Median
2.63
P/S RATIO
1.39
Industry Median
3.41
Small Cap Median
2.40
Others
PEG RATIO
0.00
EV/EBITDA RATIO
18.43
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹198.6 as on Jun 18, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company exhibits strong growth across all key metrics, including revenue, operating profit, EPS, assets, and net income. The company is expanding its operations and increasing its profitability. This suggests that the company is well-positioned for future success and has a competitive advantage in the market.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 12.97 | 4.12 | -11.76 | 4.2 | -7.9 |
| Operating Profit Growth Rate | 5.57 | -24.34 | 3.49 | 22.85 | -32.93 |
| Earnings Per Share (EPS) Growth | 20.56 | -51.15 | -11.32 | 30.5 | -153.8 |
| Asset Growth Rate | 15.68 | 7.77 | 4.28 | 1.69 | |
| Net Income Growth Rate | 20.3 | -51.25 | -10.26 | 30 | -153.85 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios are not very good, indicating potential areas of concern. The Adjusted EPS, Cash EPS, Book Value Per Share, and Dividend Per Share are all quite low. However, the Capital Expenditures (CapEx) are very strong. This is because the weighted value is 0.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 12.8 | 6.24 | 5.6 | 7.28 | |
| Cash Earnings Per Share (Cash EPS) | 20.48 | 14.96 | 15.04 | 18 | 0 |
| Book Value Per Share | 85.44 | 90.72 | 95.04 | 101.04 | |
| Dividend Per Share (DPS) | 1.56 | 1.21 | 1.18 | 0.81 | 0.59 |
| Capital Expenditures (CapEx) | 273 | 302 | 204 | 136 | 148 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company exhibits strong profitability across all key metrics, including Gross Profit Margin, ROCE, ROE, ROA, Operating Margin, and Net Margin. The company is generating healthy profits from its operations and effectively managing its expenses. This suggests that the company is well-positioned to sustain its profitability and deliver value to its shareholders.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 12.61 | 7.37 | 8.35 | 10.43 | 3.27 |
| Return on Capital Employed (ROCE) | 15 | 8 | 8 | 10 | 4 |
| Return on Equity (ROE) | 14.98 | 6.88 | 5.89 | 7.21 | |
| Return on Assets (ROA) | 15.41 | 10.82 | 10.74 | 12.97 | |
| Operating Margin | 17.55 | 12.75 | 14.96 | 17.63 | 12.84 |
| Net Margin | 8.23 | 3.86 | 3.92 | 4.89 | -2.86 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios present a mixed picture. While Days Sales in Inventory and Receivable Days are very efficient, the other efficiency ratios are not. This is because the fixed asset, inventory and receivables turnover ratios are zero. If they were non-zero, the Days Sales in Inventory and Receivable Days would also be non-zero. The capital turnover ratio is also very low. This demonstrates that Hikal is not using its assets effectively to generate revenues.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 2.21 | 2.13 | 1.67 | 1.36 | |
| Inventory Turnover Ratio | 5.7 | 5.8 | 5.27 | 5.22 | 4.96 |
| Receivables Turnover Ratio | 4.21 | 4.6 | 3.6 | 3.47 | 3.88 |
| Days Sales in Inventory Ratio | 64.04 | 62.93 | 69.26 | 69.92 | 73.59 |
| Receivable Days | 86.7 | 79.35 | 101.39 | 105.19 | 94 |
| Capital Turnover Ratio | 1.43 | 1.25 | 1.11 | 1.14 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are reasonably good, indicating a sufficient ability to meet its interest and dividend commitments. This suggests that the company is generating enough earnings to cover its interest expenses and dividend payments. While there is always room for improvement, the company's current coverage ratios provide a comfortable margin of safety.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 8.06 | 3.19 | 2.71 | 2.65 | -0.26 |
| Equity Dividend Coverage Ratio | 8.33 | 5.26 | 4.76 | 9.09 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits strong solvency, indicating a solid long-term financial position. The debt and equity ratios suggest a balanced capital structure, with a healthy proportion of equity financing. This ensures the company has a strong financial foundation and is well-positioned to manage its debt obligations. This financial stability is a significant strength for the company.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.21 | 0.3 | 0.26 | 0.23 | |
| Debt to Equity Ratio | 0.27 | 0.43 | 0.35 | 0.3 | |
| Equity Ratio | 0.79 | 0.7 | 0.74 | 0.77 | |
| Debt To Asset Ratio | 0.13 | 0.21 | 0.17 | 0.15 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position needs attention. While the Operating Cash Flow Ratio is average, the other liquidity ratios indicate potential difficulties in meeting short-term obligations. While the company generates positive cash flow from its operations, it struggles to convert its current assets into cash to cover its immediate liabilities. This situation could pose risks in managing day-to-day operations and unexpected financial needs.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.2 | 1.34 | 1.14 | 1.15 | |
| Quick Ratio | 0.81 | 0.92 | 0.79 | 0.78 | |
| Cash Ratio | 0.06 | 0.08 | 0.02 | 0.02 | |
| Operating Cash Flow Ratio | 0.34 | 0.41 | 0.21 | 0.31 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 77.43 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 35.88 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 34.17 | Neutral | 369.00 | 19.44 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 37.88 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Hikal Ltd | 7.13 | -50.15 | Neutral | 220.00 | -3.95 | -49.00 |
| 6 | RPG Life Sciences Ltd | 7.12 | 32.71 | Neutral | 147.00 | 69.64 | 115.00 |
| 7 | Morepen Laboratories Ltd | 7.12 | 29.50 | Neutral | 126.00 | 1.21 | 96.00 |
| 8 | Alembic Ltd | 7.06 | 7.59 | Undervalued | 90.00 | 4.85 | 317.00 |
| 9 | SMS Pharmaceuticals Ltd | 5.94 | 34.36 | Neutral | 171.00 | 9.35 | 102.00 |
| 10 | Gufic BioSciences Ltd | 5.49 | 55.88 | Neutral | 151.00 | 6.30 | 64.00 |
| 11 | Dishman Carbogen Amcis Ltd | 5.38 | 27.35 | Neutral | 566.00 | -2.45 | 97.00 |
| 12 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.36 | Undervalued | 269.00 | 4.69 | 138.00 |
| 13 | Indoco Remedies Ltd | 5.26 | -22.51 | Neutral | 142.00 | -0.61 | -99.00 |
| 14 | Aarti Drugs Ltd | 5.07 | 17.33 | Undervalued | 309.00 | 18.54 | 195.00 |
| 15 | Orchid Pharma Ltd | 4.85 | 248.95 | Neutral | 41.00 | 8.91 | 21.00 |
| 16 | Sequent Scientific Ltd | 4.61 | 291.78 | Overvalued | 162.00 | 0.63 | 32.00 |
| 17 | Sun Pharma Advanced Research Company Ltd | 4.35 | 5.07 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 18 | Solara Active Pharma Sciences Ltd | 4.34 | -276.85 | Neutral | 187.00 | -1.50 | -7.00 |
| 19 | Zota Health Care Ltd | 3.97 | -59.69 | Neutral | 19.00 | 8.06 | -74.00 |
The management of Hikal Ltd. demonstrates mixed performance. A consistently high promoter holding indicates strong confidence. Improving OPM points to enhanced operational efficiency. However, fluctuating sales growth and declining profit growth over the past three years raise concerns. A moderate level of debt adds to the challenges. While the management shows strengths in maintaining high promoter confidence and improving operational margins, addressing inconsistencies in revenue and profit growth is crucial for sustained performance.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 68.85% | High, indicating strong confidence |
| Improving OPM | 22% (Mar 2025) | Shows better operational efficiency | |
| CONS | Fluctuating Sales Growth | -11.79% (Mar 2024) | Inconsistent revenue expansion |
| Declining Profit Growth | -17% (3Y) | Potential sustainability concerns |
Financial Performance & Growth
Hikal Ltd.'s financial performance shows mixed results. Sales growth has been inconsistent, with a decline of -11.79% in Mar 2024. Compounded sales growth has slowed over the years. Profit growth has been volatile, with a 3-year compounded growth of -17%. The latest TTM profit growth shows improvement at 31%. OPM has improved, reaching 22% in Mar 2025, which indicates better operational efficiency. Fluctuations in quarterly sales and profit suggest some instability.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Compounded Sales Growth (%) | 6% | 20% | 8% | 4.13% | -11.79% | 4.21% |
| Compounded Profit Growth (%) | N/A | N/A | N/A | N/A | N/A | N/A |
Capital Efficiency & Returns
Capital efficiency and returns for Hikal Ltd. present a concerning picture. ROCE has declined to 10% in Mar 2025, signaling a decrease in the productive use of capital. ROE shows a similar trend. The Cash Conversion Cycle has fluctuated but generally shows moderate efficiency in working capital management.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE % | 13% | 13% | 15% | 8% | 8% | 10% |
Financial Health & Prudence
Hikal Ltd.'s financial health indicates moderate leverage. Borrowings have shown an increasing trend, with total borrowings at ₹765 Cr. in Mar 2025. The increasing borrowings suggest a moderate level of debt. Dividend payout has been consistent.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Borrowings (₹ Cr) | 533 | 631 | 644 | 748 | 818 | 765 |
Shareholding & Ownership Structure
The shareholding pattern of Hikal Ltd. shows strong promoter holding, consistently around 68.85%, indicating confidence. FII holdings have increased over time, suggesting growing interest from foreign institutional investors. DII holdings have also increased, showing greater participation from domestic institutional investors. The public float has decreased, reflecting a shift towards institutional ownership.
| Metric | Jun 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Promoter Holding (%) | 68.77 | 68.85 | 68.85 | 68.85 |
| FII Holding (%) | 3.91 | 4.56 | 6.55 | 5.70 |
| DII Holding (%) | 0.89 | 2.18 | 3.53 | 3.80 |
The risk assessment for Hikal Ltd. indicates a moderate level of concern. Overall, the company presents a moderate risk profile requiring continued monitoring.
Off-balance sheet exposure quantification
There is no available data to quantify off-balance sheet exposures for Hikal Ltd.
Contingent liability evaluation
There is no available data to evaluate contingent liabilities for Hikal Ltd.
Regulatory compliance cost trends
There is no data available regarding regulatory compliance cost trends for Hikal Ltd.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe